Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H21NO3.C4H6O6 |
Molecular Weight | 449.4511 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.COC1=C2O[C@H]3C(=O)CC[C@H]4[C@H]5CC(C=C1)=C2[C@@]34CCN5C
InChI
InChIKey=OJHZNMVJJKMFGX-BWCYBWMMSA-N
InChI=1S/C18H21NO3.C4H6O6/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;5-1(3(7)8)2(6)4(9)10/h3,6,11-12,17H,4-5,7-9H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-,12+,17-,18-;1-,2-/m01/s1
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C18H21NO3 |
Molecular Weight | 299.3642 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Benzhydrocodone is a prodrug of hydrocodone. Benzhydrocodone is formed by covalently bonding hydrocodone to benzoic acid. Benzhydrocodone itself is not pharmacologically active, but must be metabolized to hydrocodone by enzymes in the intestinal tract to optimally deliver its pharmacologic effects. Hydrocodone is a full agonist of the opioid receptors with a higher affinity for the mu-opioid receptor. Upon binding, hydrocodone produces an analgesic effect with no ceiling. APADAZ a combination of benzhydrocodone and acetaminophen is FDA approved and indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. APADAZ, even when taken as recommended, can result in addiction, abuse, and misuse, which can lead to overdose and death.
CNS Activity
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZOHYDRO ER Approved UseZOHYDRO ER is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Launch Date2013 |
|||
Primary | APADAZ Approved UseAPADAZ is a combination of benzhydrocodone, a prodrug of the opioid agonist hydrocodone, and acetaminophen, and is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Launch Date2019 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27138027/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27138027/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
23.6 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
16.04 ng/mL |
6.12 mg single, oral dose: 6.12 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
19.18 ng/mL |
6.12 mg single, oral dose: 6.12 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
33.95 ng/mL |
12.24 mg 6 times / day multiple, oral dose: 12.24 mg route of administration: Oral experiment type: MULTIPLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
62.79 ng/mL |
12.24 mg 6 times / day multiple, oral dose: 12.24 mg route of administration: Oral experiment type: MULTIPLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
208 ng/mL |
73.44 mg single, oral dose: 73.44 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.4 ng/mL |
6.12 mg single, nasal dose: 6.12 mg route of administration: Nasal experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
27 ng/mL |
24.48 mg single, nasal dose: 24.48 mg route of administration: Nasal experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
25.6 ng/mL |
12.24 mg single, nasal dose: 12.24 mg route of administration: Nasal experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
40.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29025138/ |
12.24 mg single, oral dose: 12.24 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
34.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29025138/ |
12.24 mg single, nasal dose: 12.24 mg route of administration: Nasal experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
269 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27138027/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
155 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27138027/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
130.91 ng × h/mL |
6.12 mg single, oral dose: 6.12 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
125.73 ng × h/mL |
6.12 mg single, oral dose: 6.12 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
92.94 ng × h/mL |
12.24 mg 6 times / day multiple, oral dose: 12.24 mg route of administration: Oral experiment type: MULTIPLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
195.07 ng × h/mL |
12.24 mg 6 times / day multiple, oral dose: 12.24 mg route of administration: Oral experiment type: MULTIPLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1272 ng × h/mL |
73.44 mg single, oral dose: 73.44 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
194.7 ng × h/mL |
12.24 mg single, nasal dose: 12.24 mg route of administration: Nasal experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
252.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29025138/ |
12.24 mg single, oral dose: 12.24 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
278.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29025138/ |
12.24 mg single, nasal dose: 12.24 mg route of administration: Nasal experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27138027/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
10.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27138027/ |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.51 h |
6.12 mg single, oral dose: 6.12 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
4.33 h |
6.12 mg single, oral dose: 6.12 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT |
|
4.45 h |
12.24 mg 6 times / day multiple, oral dose: 12.24 mg route of administration: Oral experiment type: MULTIPLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.87 h |
12.24 mg 6 times / day multiple, oral dose: 12.24 mg route of administration: Oral experiment type: MULTIPLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5 h |
73.44 mg single, oral dose: 73.44 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
5.29 h |
12.24 mg single, nasal dose: 12.24 mg route of administration: Nasal experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
55% |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCODONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg multiple, oral Overdose |
unhealthy, 5 years |
Other AEs: Adverse event... |
160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Electrocardiogram QTc interval prolonged... Other AEs: Electrocardiogram QTc interval prolonged Sources: |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
Other AEs: Withdrawal syndrome neonatal... Other AEs: Withdrawal syndrome neonatal Sources: |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Respiratory depression, Addiction... Other AEs: Respiratory depression (grade 5) Sources: Addiction |
20 mg 1 times / day multiple, oral Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Disc. AE: Vomiting, Nausea... AEs leading to discontinuation/dose reduction: Vomiting (1%) Sources: Nausea (1%) Headache (1%) Dizziness (1%) |
13.34 mg 1 times / day steady-state, intranasal Studied dose Dose: 13.34 mg, 1 times / day Route: intranasal Route: steady-state Dose: 13.34 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Nasal discomfort, Nasal congestion... Other AEs: Nasal discomfort (16 patients) Sources: Nasal congestion (7 patients) Rhinorrhea (7 patients) Throat irritation (6 patients) Oropharyngeal pain (1 pt) Dry throat (1 pt) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Adverse event | grade 5 | 30 mg multiple, oral Overdose |
unhealthy, 5 years |
Electrocardiogram QTc interval prolonged | 160 mg 1 times / day multiple, oral Highest studied dose Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Withdrawal syndrome neonatal | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: |
|
Addiction | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
Respiratory depression | grade 5 | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Dizziness | 1% Disc. AE |
20 mg 1 times / day multiple, oral Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Headache | 1% Disc. AE |
20 mg 1 times / day multiple, oral Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Nausea | 1% Disc. AE |
20 mg 1 times / day multiple, oral Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Vomiting | 1% Disc. AE |
20 mg 1 times / day multiple, oral Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: |
Dry throat | 1 pt | 13.34 mg 1 times / day steady-state, intranasal Studied dose Dose: 13.34 mg, 1 times / day Route: intranasal Route: steady-state Dose: 13.34 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Oropharyngeal pain | 1 pt | 13.34 mg 1 times / day steady-state, intranasal Studied dose Dose: 13.34 mg, 1 times / day Route: intranasal Route: steady-state Dose: 13.34 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Nasal discomfort | 16 patients | 13.34 mg 1 times / day steady-state, intranasal Studied dose Dose: 13.34 mg, 1 times / day Route: intranasal Route: steady-state Dose: 13.34 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Throat irritation | 6 patients | 13.34 mg 1 times / day steady-state, intranasal Studied dose Dose: 13.34 mg, 1 times / day Route: intranasal Route: steady-state Dose: 13.34 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Nasal congestion | 7 patients | 13.34 mg 1 times / day steady-state, intranasal Studied dose Dose: 13.34 mg, 1 times / day Route: intranasal Route: steady-state Dose: 13.34 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Rhinorrhea | 7 patients | 13.34 mg 1 times / day steady-state, intranasal Studied dose Dose: 13.34 mg, 1 times / day Route: intranasal Route: steady-state Dose: 13.34 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf#page=29 Page: 29.0 |
minor | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206627s007s008lbl.pdf#page=29 Page: 29.0 |
minor | |||
yes | yes (co-administration study) Comment: The 90% confidence interval (CI) of the geometric means for hydrocodone AUCinf (98 to 115%), AUCt (98 to 115%), and Cmax (93 to 121%) values were within the range of 80 to 125% when a single dose of HYSINGLA ER 20 mg was co-administered with CYP2D6 inhibitor paroxetine |
|||
yes | yes (co-administration study) Comment: Co-administration of HYSINGLA ER and CYP3A4 inhibitor ketoconazole increased mean hydrocodone AUC and Cmax by 135% and 78%, respectively; |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206627Orig1s000PharmR.pdf#page=33 Page: 33.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Opioid formulations: tailoring to the needs in chronic pain. | 2001 |
|
Harmonic Scalpel vs. electrocautery hemorrhoidectomy: a prospective evaluation. | 2001 Apr |
|
Psychosis after ultrarapid opiate detoxification. | 2001 Jun |
|
Narcotic analgesics for dental pain: available products, strengths, and formulations. | 2001 Mar-Apr |
|
Important drugs for cough in advanced cancer. | 2001 Nov |
|
Acetaminophen, aspirin, or Ibuprofen in combination analgesic products. | 2001 Nov-Dec |
|
Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. | 2001 Sep |
|
Complications of intranasal prescription narcotic abuse. | 2002 Feb |
|
The effectiveness of an anesthetic continuous-infusion device on postoperative pain control. | 2002 Jan |
|
Synthesis and biological activity of 8beta-substituted hydrocodone indole and hydromorphone indole derivatives. | 2002 Jan 21 |
|
Gateways to clinical trials. | 2002 Jul-Aug |
|
A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery. | 2002 Jun |
|
[Trends in the incidence of hepatic tumors in childhood]. | 2002 Mar-Apr |
|
Detection of cocaine analytes and opiates in nails from postmortem cases. | 2002 Oct |
|
[Hypoxic brain damage in victims of fatal road traffic accident: prevalence, distribution and association with survival time and other head and extracranial injuries]. | 2002 Sep |
|
Review of the analgesic efficacy of ibuprofen. | 2003 Apr |
|
Current concepts in acute pain management. | 2003 May |
|
[Spanish scientific production in anesthesiology and resuscitation 1983-1995]. | 2003 Nov |
|
Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. | 2003 Nov |
|
The influence of gender and race on physicians' pain management decisions. | 2003 Nov |
|
Refractory status epilepticus. | 2004 Feb |
|
Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor. | 2004 Feb |
|
Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. | 2004 Feb |
|
Postoperative pain management after anterior cruciate ligament reconstruction. | 2004 Jan |
|
Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone. | 2004 Jan-Feb |
|
Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. | 2004 Jun |
|
Hallucinations with zolpidem and fluoxetine in an impaired driver. | 2004 Mar |
|
CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. | 2004 Mar |
|
[Gender and health in the daily press]. | 2004 May |
|
[Origin and growth of the National Program of Continuous Academic Development for the General Physician]. | 2004 May-Jun |
|
Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. | 2004 Oct |
|
A 35-year-old physician with opioid dependence. | 2004 Sep 15 |
|
Selective potentiation of opioid analgesia by nonsteroidal anti-inflammatory drugs. | 2005 Apr 8 |
|
The GC-MS detection and characterization of neopine resulting from opium use and codeine metabolism and its potential as an opiate-product-use marker. | 2005 Jun |
|
A 46-year-old man with excruciating shoulder pain. | 2005 Mar |
|
Oral analgesics for acute nonspecific pain. | 2005 Mar 1 |
Sample Use Guides
APADAZ Immediate-release tablets: 6.12 mg benzhydrocodone (equivalent to 6.67 mg benzhydrocodone hydrochloride) and 325 mg acetaminophen.
Initiate treatment with APADAZ at 1 or 2 tablets every 4 to 6 hours as needed for pain. Dosage should not exceed 12 tablets in a 24 hour period.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:06:33 GMT 2025
by
admin
on
Mon Mar 31 20:06:33 GMT 2025
|
Record UNII |
9GU1G05Y03
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9GU1G05Y03
Created by
admin on Mon Mar 31 20:06:33 GMT 2025 , Edited by admin on Mon Mar 31 20:06:33 GMT 2025
|
PRIMARY | |||
|
143-71-5
Created by
admin on Mon Mar 31 20:06:33 GMT 2025 , Edited by admin on Mon Mar 31 20:06:33 GMT 2025
|
PRIMARY | |||
|
100000091919
Created by
admin on Mon Mar 31 20:06:33 GMT 2025 , Edited by admin on Mon Mar 31 20:06:33 GMT 2025
|
PRIMARY | |||
|
SUB32412
Created by
admin on Mon Mar 31 20:06:33 GMT 2025 , Edited by admin on Mon Mar 31 20:06:33 GMT 2025
|
PRIMARY | |||
|
m6093
Created by
admin on Mon Mar 31 20:06:33 GMT 2025 , Edited by admin on Mon Mar 31 20:06:33 GMT 2025
|
PRIMARY | |||
|
DTXSID40162277
Created by
admin on Mon Mar 31 20:06:33 GMT 2025 , Edited by admin on Mon Mar 31 20:06:33 GMT 2025
|
PRIMARY | |||
|
205-608-1
Created by
admin on Mon Mar 31 20:06:33 GMT 2025 , Edited by admin on Mon Mar 31 20:06:33 GMT 2025
|
PRIMARY | |||
|
5463977
Created by
admin on Mon Mar 31 20:06:33 GMT 2025 , Edited by admin on Mon Mar 31 20:06:33 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
SUBSTANCE->BASIS OF STRENGTH | |||
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |